Clinical Observation of Sintilimab Combined with Pemetrexed+cisplatin Chemotherapy in the Treatment of Non-small Cell Lung Cancer
Objective To observe the clinical efficacy of Sintilimab combined with pemetrexed+cisplatin in the treat-ment of non-small cell lung cancer(NSCLC).Methods The clinical data of 93 NSCLC patients were retrospectively analyzed.54 patients who were treated with pemetrexed+cisplatin were included in the control group,and 39 patients who were treated with Si-ntilimab combined with pemetrexed+cisplatin were included in the combined group.The short-term efficacy,tumor marker[CY-FRA21-1,Carcinoembryonic antigen,CA1 25]levels,immune function indicators(CD3+,CD4+,CD8+,CD4+/CD8+)and ad-verse drug reactions(gastrointestinal reactions,hematopoietic system abnormalities,rashes,liver and kidney dysfunction,thyroid dysfunction)were compared between the 2 groups.Results After treatment,the disease control rate(DCR)of the combined group was higher than that of the control group,with a statistical significant difference(P＜0.05).There was no statistical signifi-cant difference in the objective response rate(ORR)between the 2 groups(P＞0.05).After treatment,CYFRA21-1,CEA,and CA125 in both groups decreased compared to before treatment,and the combined group was lower than the control group(P＜0.05).After treatment,the CD3+,CD4+,CD4+/CD8+levels in the combined group increased compared to before treatment,while CD8+levels decreased compared to before treatment.The CD3+,CD4+,CD4+/CD8+levels in the control group decreased compared to before treatment,while CD8+levels increased compared to before treatment(P＜0.05).During the treatment process,there was no statistical significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sintilimab combined with pemetrexed+cisplatin chemotherapy has good short-term efficacy in the treatment of NSCLC,which can reduce the level of tumor markers,improve the immune function of the body,and has good drug safety.
NETL
NSTL
万方数据
